Philips has introduced SmartIQ, a new artificial intelligence (AI)-based software algorithm for improving image quality and optimising radiation dosing during coronary imaging procedures.
Designed for Philips Azurion image-guided therapy platform, SmartIQ is intended to address what the Netherlands-based company calls one of the ‘most fundamental’ challenges in coronary imaging: the trade-off between image quality and radiation exposure for patients and clinical staff.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
SmartIQ, which has achieved a European CE mark but is not yet cleared in the US, ideates on Philips’ existing ClarityIQ tool, a software built into its Azurion platform for reducing X-ray radiation doses while preserving image quality. According to the company, SmartIQ’s ultra-low dose protocol for coronary procedures employs over 50% less X-ray radiation doses versus the lowest dose settings available with ClarityIQ.
Philips published results from the first blinded clinical pilot study evaluating SmartIQ in the Journal of the Society for Cardiovascular Angiography & Interventions on 12 May. With ClarityIQ used as a comparator, Philips stated that the pilot’s results indicate that SmartIQ scored higher on image quality and was preferred in the vast majority of blinded comparisons, while maintaining or lowering radiation and contrast dose.
Further evidence surrounding SmartIQ’s impact on radiation dosing compared to ClarityIQ is being generated in the ongoing RADIQAL trial (NCT06944509), which recently hit 60% enrolment, Philips stated.
SmartIQ is being debuted at the 2026 EuroPCR conference, taking place in Paris, France, between 19–22 May.
Mark Stoffels, business leader for image-guided therapy systems at Philips, said: “For too long, clinicians have had to choose between image quality and radiation dose during coronary procedures.
“With our breakthrough SmartIQ technology, we believe that trade-off no longer has to define coronary imaging. This is not an incremental step forward – it represents one of Philips’ boldest advances yet in helping clinicians see what they need while aiming to further reduce exposure for patients and clinical teams.”
AI is having a vast impact in healthcare, taking up a particularly dominant role in the medical imaging space. According to a report by GlobalData, the combined AI market across healthcare was valued at $11.9bn in 2024 and is expected to reach a valuation of $57.4bn in 2029.
